Invited Commentary: Understanding the Fibromyalgia Syndrome

In this edition, Rao et al. have updated their previous review of the psychopharmacology of fibromyalgia. Indeed, much has happened since the publication by Kranzler et al., including the approval, by the US Food and Drug Administration, of pregabalin for the management of fibromyalgia, and the subsequent submission of two additional compounds for regulatory review. Rao et al. provide an excellent review of the topic; this commentary intends to supplement their review with additional, contemporary data.